Heron Therapeutics (HRTX) Change in Account Payables (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Change in Account Payables data on file, last reported at -$24000.0 in Q1 2026.

• Quarterly Change in Account Payables fell 103.85% year-over-year to -$24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 129.25% YoY) and the FY2025 annual result came in at -$2.7 million, down 132.06% from the prior year.
• Change in Account Payables climbed to -$24000.0 in Q1 2026, from -$3.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $9.4 million in Q2 2024 to a low of -$7.3 million in Q3 2022.
• A 5-year average of $303941.2 and a median of -$24000.0 in 2026 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 545.4% in 2024, down 386.07% in 2024.
• Tracing HRTX's Change in Account Payables over 5 years: stood at -$3.3 million in 2022, then surged by 141.54% to $1.4 million in 2023, then climbed by 10.22% to $1.5 million in 2024, then slumped by 298.75% to -$3.0 million in 2025, then jumped by 99.21% to -$24000.0 in 2026.
• The last three Change in Account Payables figures came in at -$24000.0 (Q1 2026), -$3.0 million (Q4 2025), and -$20000.0 (Q3 2025), per Business Quant data.